Ataxia Clinical Trial - RFC1 Natural History Study

Status Recruiting

Clinical Trial Summary

This international, multi-center, multi-modal and prospective observational study aims to determine the phenotypic spectrum and the natural progression of the RFC1 repeat expansion disease, and to seek and validate digital, imaging, and molecular biomarkers that aid in diagnosis and serve as outcome measures in future clinical trials of this novel, but frequent ataxia with late adult-onset.

Clinical Trial Description

The investigators will perform an international, multi-center, multi-modal, and registry-based standardized prospective Natural History Study (NHS) in RFC1 repeat expansion disease. Participants will be assessed annually. Study visits with a standardized clinical examination will apply several clinical rating scales, and data will be entered into a clinical database (ARCA Registry; www.ARCA-registry.org) customized to the requirements of this specific study. At all study visits, patients will be asked to donate biosamples; biomaterial collection is optional, and participants can elect to participate in sampling of blood, urine, CSF, and/or a skin biopsy. Optionally, and depending on local availability at each participating site, additional examinations may be performed including imaging, quantitative movement and speech analysis, vestibular testing, a neuropsychological examination, or examination of swallowing function, all to fully capture the multisystemic presentation of the RFC1 repeat expansion disease. This study will delineate variable phenotypes of this relatively novel disease, and systematically characterize the longitudinal progression of multi-model biomarkers to determine the most sensitive, comprehensive, and reliable outcomes measures for future therapeutic trials. Here, longitudinal validation of targeted fluid biomarker candidates will be an important part. The multi-modal longitudinal design of the study and its comprehensive assessment will also provide mechanistic insights into the multisystemic evolution of the disease, which will especially allow to track and understand selective as well as overlapping dysfunction of the cerebellum, sensory peripheral nerves, the vestibular system, and additional systems known to be involved in RFC1 disease or 'CANVAS' as its related syndrome. ;

Study Design

Related Conditions & MeSH terms

Ataxia

Clinical Trial Details

NCT number	NCT05177809
Study type	Observational [Patient Registry]
Source	University Hospital Tuebingen
Contact	Matthis Synofzik, Prof. Dr.
Phone	+49 7071 29
Email	matthis.synofzik@uni-tuebingen.de
Status	Recruiting
Phase
Start date	December 14, 2021
Completion date	December 2025

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03722212` - Early Diagnosis of the GLUT1 Deficiency Syndrome With a Blood Based Test	N/A
Completed	`NCT05563402` - "Evaluation of Usability and Safety of the Self-balancing Walking System Atalante in Patients With Multiple Sclerosis"	N/A
Terminated	`NCT03645265` - Rhythmic Entrainment in Bilingual Speakers With Dysarthria	N/A
Completed	`NCT05585541` - Teleassessment in Ataxic Multiple Sclerosis
Recruiting	`NCT05125666` - Efficacy of Dual Task Training on Children With Ataxia After Medulloblastoma Resection	Phase 2
Recruiting	`NCT03881930` - Balance Rehabilitation With Modified Visual Input in Patients With Neuropathy	N/A
Completed	`NCT00950196` - Amantadine for Improving Neurologic Symptoms in Ataxia-Telangiectasia	Phase 4
Completed	`NCT04183647` - Investigation of Acute Effects of Local Vibration and Whole-Body Vibration Applications	N/A
Completed	`NCT03745248` - Aerobic Exercise, Balance Training, and Ataxia	N/A
Completed	`NCT04099914` - Validation of a Clinical Algorithm for the Diagnosis of Recessive Ataxias
Recruiting	`NCT03945682` - The ASsessment and Physiotherapy managEment of Ataxia in Children Following Surgical Resection of Posterior Fossa Tumour	N/A
Completed	`NCT01428544` - Special Drug Use Investigation (Retrospective) for Arixtra® (Fondaparinux) Venous Thromboembolism Treatment (Over 100kg)	N/A
Completed	`NCT00001324` - PET Scan to Study Brain Control of Human Movement
Recruiting	`NCT05486806` - Longitudinal Tracking of Patients Diagnosed With Neurodegenerative Movement Disorders
Completed	`NCT06001424` - Effect of Life Kinetik Training on Lower Limb Coordination in Ataxic Patients	N/A
Completed	`NCT00244361` - Effectiveness of Rituximab in Pediatric OMS Patients.	Phase 1/Phase 2
Completed	`NCT00692861` - Autoimmunity in Neurologic Complications of Celiac Disease
Recruiting	`NCT05885282` - Investigation of the Effects of Local Vibration Applied to Different Regions and Spinal Stabilization Exercises	N/A
Recruiting	`NCT02841553` - Wolfram Syndrome and WFS1-related Disorders International Registry and Clinical Study
Not yet recruiting	`NCT06420271` - Effects of Cerebellar tACS-iTBS in Ataxia	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

RFC1 Natural History Study — RFC1-NHS

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms